Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Non-Current Liabilities (2024 - 2025)

Crinetics Pharmaceuticals has reported Other Non-Current Liabilities over the past 2 years, most recently at $3.2 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 290.83% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $3.2 million, up 290.83%, while the annual FY2025 figure was $3.2 million, 290.83% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $3.2 million at Crinetics Pharmaceuticals, up from $2.9 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $3.2 million in Q4 2025 and troughed at $202000.0 in Q2 2024.